Featured Research

from universities, journals, and other organizations

Ground breaking research identifies promising drugs for treating Parkinson's

Date:
September 3, 2013
Source:
University of Sheffield
Summary:
New drugs, which may have the potential to stop faulty brain cells dying and slow down the progression of Parkinson's, have been identified by scientists in a pioneering study which is the first of its kind.

Brain of patient with Parkinson's disease.
Credit: Modified from Obeso JA et al. Nat. Med. 2010

New drugs which may have the potential to stop faulty brain cells dying and slow down the progression of Parkinson's, have been identified by scientists in a pioneering study which is the first of its kind.

Experts from the world leading Sheffield Institute for Translational Neuroscience (SITraN) conducted a large scale drugs trial in the lab using skin cells from people with this progressive neurological condition which affects one in every 500 people in the UK.

The researchers tested over 2,000 compounds to find out which ones could make faulty mitochondria work normally again.

Mitochondria act as the power generators in all cells of our body, including the brain. Malfunctioning mitochondria are one of the main reasons why brain cells die in Parkinson's.

One of the promising medications identified though the research is a synthetic drug called ursodeoxycholic acid (UDCA).

This licenced drug has been in clinical use for several decades to treat certain forms of liver disease which means that researchers will be able to immediately start a clinical trial to test its safety and tolerability in people with Parkinson's.

This will discover the optimum dose to ensure that enough of the drug reaches the part of the brain where Parkinson's develops.

Based on this information, larger randomized controlled trials can be carried out to assess the potential of UDCA to treat Parkinson's.

The extensive drug screen, which took over five years to complete, was funded by leading research charity Parkinson's UK, and was carried out in collaboration with the University of Trondheim, Norway.

Dr Oliver Bandmann, Reader in Neurology at SITraN, said: "Parkinson's is so much more than just a movement disorder.

It can also lead to depression and anxiety, and a host of distressing day to day problems like bladder and bowel dysfunction.

"The best treatments currently available only improve some of the symptoms, rather than tackle the reason why Parkinson's develops in the first place, so there is a desperate need for new drug treatments which could actually slow down the disease progression."

"We are hopeful that this group of drugs can one day make a real difference to the lives of people with Parkinson's."

The results of the ground breaking study are published in the leading Neuroscience journal BRAIN.

Dr Kieran Breen, Director of Research and Innovation at Parkinson's UK commented: "This is a really exciting time for Parkinson's research. For the first time, we are starting to identify drugs that will treat the Parkinson's -- possibly slow down or halt its progression -- rather than just the symptoms.

"This will bring us closer to our ultimate goal of a cure for Parkinson's. We look forward to working closely with Dr Bandmann to develop this treatment."


Story Source:

The above story is based on materials provided by University of Sheffield. Note: Materials may be edited for content and length.


Journal Reference:

  1. H. Mortiboys, J. Aasly, O. Bandmann. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain, 2013; DOI: 10.1093/brain/awt224

Cite This Page:

University of Sheffield. "Ground breaking research identifies promising drugs for treating Parkinson's." ScienceDaily. ScienceDaily, 3 September 2013. <www.sciencedaily.com/releases/2013/09/130903123524.htm>.
University of Sheffield. (2013, September 3). Ground breaking research identifies promising drugs for treating Parkinson's. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/09/130903123524.htm
University of Sheffield. "Ground breaking research identifies promising drugs for treating Parkinson's." ScienceDaily. www.sciencedaily.com/releases/2013/09/130903123524.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins